Fig. 9
MIR4435-2HG sensitizes pancreatic cancer stem cells to ferroptosis.(A) The expression levels of GPX4 and SLC7A11 positively correlate with the co-expression of MIR4435-2HG. (B) Western blot analysis of GPX4 and SLC7A11 in cells with MIR4435-2HG knockdown and overexpression. (C) Relative cell viability and IC50 values for MIR4435-2HG knockdown and overexpressing cells following gemcitabine (GEM) treatment. (D) Relative cell viability of MIR4435-2HG knockdown cells co-transfected with STAT1 after gemcitabine (GEM) therapy. (E) Relative OD450 values for BxPC-3 control and MIR4435-2HG overexpressing cells treated with GEM, GEM + 0.1 μM RSL3, and GEM + 1 μM RSL3. Corresponding OD450 values for PANC-1 control and MIR4435-2HG overexpressing cells treated with GEM, GEM + 10 nM RSL3, and GEM + 100 nM RSL3. (F) Representative flow cytometry plots showing ROS levels and percentages in MIR4435-2HG knockdown cells and those co-transfected with STAT1. (G) Measurement of ATP levels, GSH levels, and iron content in MIR4435-2HG knockdown cells and MIR4435-2HG co-transfected with STAT1 cells *p<0.05, **p<0.01, ***p<0.001